Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ethan Dmitrovsky

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2018
Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancersMasanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
International Journal of Oncology|August 28, 2012
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutationsFabrizio Galimberti, Alexander M Busch, Fadzai Chinyengetere, et al.
JCI Insight|May 19, 2026
Derivation and characterization of ubiquitin-specific protease 18 inhibitorsBlessing O Ogunlade, Kevin N Dalby, Samuel C Okpechi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 4, 2011
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic modelsKonstantin H Dragnev, Tian Ma, Jobin Cyrus, et al.
Molecular Cancer Therapeutics|May 21, 2013
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancerTian Ma, Fabrizio Galimberti, Cherie P Erkmen, et al.
Scientific Reports|September 9, 2023
A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironmentCheng-Hsin Wei, Lu Huang, Blair Kreh, et al.
Molecular Cancer Therapeutics|December 5, 2020
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid CancersMasanori Kawakami, Lisa Maria Mustachio, Yulong Chen, et al.
BMC Cancer|November 12, 2015
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomasFadzai Chinyengetere, David J Sekula, Yun Lu, et al.
Journal of the National Cancer Institute|April 5, 2017
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung CancerMasanori Kawakami, Lisa Maria Mustachio, Jaime Rodriguez-Canales, et al.
Molecular Cancer Research : MCR|March 1, 2017
Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung CancerLisa Maria Mustachio, Yun Lu, Laura J Tafe, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2018
Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancersMasanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
International Journal of Oncology|August 28, 2012
Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutationsFabrizio Galimberti, Alexander M Busch, Fadzai Chinyengetere, et al.
JCI Insight|May 19, 2026
Derivation and characterization of ubiquitin-specific protease 18 inhibitorsBlessing O Ogunlade, Kevin N Dalby, Samuel C Okpechi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 4, 2011
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic modelsKonstantin H Dragnev, Tian Ma, Jobin Cyrus, et al.
Molecular Cancer Therapeutics|May 21, 2013
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancerTian Ma, Fabrizio Galimberti, Cherie P Erkmen, et al.
Scientific Reports|September 9, 2023
A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironmentCheng-Hsin Wei, Lu Huang, Blair Kreh, et al.
Molecular Cancer Therapeutics|December 5, 2020
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid CancersMasanori Kawakami, Lisa Maria Mustachio, Yulong Chen, et al.
BMC Cancer|November 12, 2015
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomasFadzai Chinyengetere, David J Sekula, Yun Lu, et al.
Journal of the National Cancer Institute|April 5, 2017
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung CancerMasanori Kawakami, Lisa Maria Mustachio, Jaime Rodriguez-Canales, et al.
Molecular Cancer Research : MCR|March 1, 2017
Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung CancerLisa Maria Mustachio, Yun Lu, Laura J Tafe, et al.
Pageof 9